Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 15 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March New on NCI’s Websites for March 2025 MOST POPULAR Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node... August 31, 2021 News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and... June 20, 2020 FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma July 12, 2022 Peace May 19, 2021 Load more HOT NEWS Engaging People with Low-Grade Glioma in Cancer Research Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 Workout Wednesday – Back Stretches Part 2 What is Mindfulness?